BriaCell Therapeutics (BCT.TO) was last seen up 3.6% after the company on Tuesday released new positive data in its Phase 2 metastatic breast cancer (MBC) study.

In the study, patients treated with the same Bria-IMT regimen formulation being used in the ongoing Phase 3 pivotal trial experienced a one-year survival rate of 55% (i.e. 55% of patients remain alive at least one year after starting on the study). This rate exceeds the survival data of the current standard of care for similar patients. Four of the 13 patients recruited in 2022 remain in survival follow-up.

According to the statement, final median overall survival calculation for the Phase 2 study is pending, as many patients remain alive. Furthermore, no Bria-IMT related discontinuations have been reported.

"With over 40,000 deaths each year in the US alone, late-stage MBC remains an important unmet medical need for many patients and their families. Approved treatments are restricted by poor survival and harsh side effects," said Adam Brufsky, Professor of Medicine at the University of Pittsburgh School of Medicine. "We are impressed with BriaCell's promising randomized Phase 2 survival data indicating robust survival and a preferred tolerability profile for Bria-IMT and look forward to seeing the data being replicated in BriaCell's pivotal Phase 3 study."

BriaCell was last seen up $0.04 to $1.15 on the Toronto Stock Exchange.